Bfsg LLC Sells 300 Shares of Edwards Lifesciences Co. (NYSE:EW)

Bfsg LLC cut its position in Edwards Lifesciences Co. (NYSE:EW) by 4.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,095 shares of the medical research company’s stock after selling 300 shares during the quarter. Bfsg LLC’s holdings in Edwards Lifesciences were worth $541,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. SG Americas Securities LLC grew its position in shares of Edwards Lifesciences by 4.9% in the third quarter. SG Americas Securities LLC now owns 37,480 shares of the medical research company’s stock valued at $2,597,000 after purchasing an additional 1,734 shares in the last quarter. Flagship Harbor Advisors LLC grew its position in Edwards Lifesciences by 9.7% during the third quarter. Flagship Harbor Advisors LLC now owns 10,266 shares of the medical research company’s stock worth $711,000 after buying an additional 907 shares in the last quarter. Caprock Group LLC grew its position in Edwards Lifesciences by 4.8% during the third quarter. Caprock Group LLC now owns 8,611 shares of the medical research company’s stock worth $597,000 after buying an additional 392 shares in the last quarter. RDA Financial Network grew its position in Edwards Lifesciences by 4.7% during the third quarter. RDA Financial Network now owns 20,758 shares of the medical research company’s stock worth $1,438,000 after buying an additional 928 shares in the last quarter. Finally, Oak Thistle LLC purchased a new position in Edwards Lifesciences during the third quarter worth about $700,000. 79.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Royal Bank of Canada boosted their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Morgan Stanley upped their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Mizuho upped their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Citigroup upped their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Finally, Stifel Nicolaus upped their price target on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $91.73.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $92.42, for a total value of $2,712,527.00. Following the transaction, the director now owns 4,486 shares of the company’s stock, valued at approximately $414,596.12. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 over the last ninety days. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded up $0.86 during trading on Wednesday, reaching $88.61. The company had a trading volume of 3,234,911 shares, compared to its average volume of 3,823,988. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12. The firm’s 50-day simple moving average is $90.18 and its 200 day simple moving average is $78.62. The firm has a market capitalization of $53.34 billion, a price-to-earnings ratio of 38.14, a price-to-earnings-growth ratio of 4.31 and a beta of 1.05. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting analysts’ consensus estimates of $0.64. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the firm earned $0.64 earnings per share. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.